Compare Amgen, Inc. (AMGN) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs LTC Properties Inc — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while LTC Properties Inc trades at $38.12 (market cap $2.12B). The key difference: Amgen, Inc. is far larger — about 106.5× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.78%). Which is the better fit depends on your goals.
| AMGN | LTC | |
|---|---|---|
Market Cap | $225.71B | $2.12B |
Sector | Health | Real Estate |
52-Week High | $417.20 | $42.81 |
52-Week Low | $271.18 | $33.98 |
Enterprise Value | $269.02B | $2.86B |
Dividend Yield | 2.42% | 5.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
LTC Properties trades at $39.85, up 1.01% today, with a bullish technical signal supported by moving averages. The REIT shows strong fundamentals with a 14.08 P/E ratio, 38.93% net income margin, and consistent dividend payments of $0.19 monthly. Recent acquisitions in seniors housing (SHOP) portfolio total $285 million year-to-date, driving revenue growth from $210M in 2024 to $263M in 2025. However, earnings misses in two of the last three quarters and rising debt-to-asset ratio to 42.64% warrant caution.
Outlook remains positive due to demographic tailwinds in senior housing and aggressive SHOP expansion, but investors face risks from execution challenges in acquisitions and interest rate sensitivity. Analyst consensus is mixed with 27% buy ratings versus 59% hold, suggesting cautious optimism amid transition phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
